Skip to content

Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization

The Relationship Between Basal Androgen Levels and the Needing of LH for Controlled Ovarian Stimulation for in Vitro Fertilization

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01563809
Enrollment
400
Registered
2012-03-27
Start date
2008-12-31
Completion date
2010-12-31
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Basing the investigators study on the evidence that basal serum androgens decrease with age, the investigators hypothesize that women with serum androgens below a certain level could be the population obtaining a benefit of Luteinizing Hormone (LH) supplementation. The objective of the present study is to explore the relationship between basal serum androgen levels and the need of LH for Controlled Ovarian Stimulation (COS) in IVF.

Detailed description

Design: Single centre, open label, randomized controlled trial. * Population: Patients with indication of In Vitro Fertilization (IVF) with the following criteria: * Protocol: All patients are tested on day 3-5 of cycle for total Testosterone (Te), Dehydroepiandrosetnodione sulphate (DHEAS) and Androstenodione (Δ4). Samples are frozen and stored at -20ºC for later analysis. FSH, LH, E2, PRL and TSH are also determined. All patients follow Controlled Ovarian Stimulation for IVF with a GnRH agonist long protocol. They are randomized to receive recombinant (r) FSH alone (225 IU/day) or r-FSH + r-LH (225+75 IU/day). * Sample size calculation: To detect a difference from 40 to 60% (Relative risk: 1.50) on pregnancy rate (PR) between patients with low and high androgen levels with respect to the mean of each COS protocol, with a confidence level of 95% (error α=0.05) and 80% of power (error β=0.2), 97 patients per arm were needed. (n=388 patients). Rounding up, 400 patients are to be recruited.

Interventions

DRUGFSH+LH

75 IU of LH will be given from stimulation day 1

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
Yes

Inclusion criteria

* 1st-2nd IVF cycle * Regular cycle (25-35 days) * Age 18 - 42 * BMI: 18-29.9

Exclusion criteria

* LH:FSH \> 2 * Low response background (\< 5 oocytes) * Recurrent pregnancy loss * Preimplantational genetic diagnosis indication * Any systemic, metabolic or endocrinological disorder.

Design outcomes

Primary

MeasureTime frameDescription
Clinical Pregnancy Rate45 daysUse of rec LH supplementation for controlled ovarian stimulation for IVF

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026